{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:39Z","timestamp":1793234319775,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alterations in the production of short-chain fatty acids (SCFAs) may reflect disturbances in the gut microbiota and have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD). We assessed plasma SCFAs in patients with MASLD and healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fasting venous blood samples were collected and eight SCFAs were measured using gas chromatography-tandem mass spectrometry (GC-MS\/MS). Relative between-group differences in circulating SCFA concentrations were estimated by linear regression, and the relation between SCFA concentrations, MASLD, and fibrosis severity was investigated using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study includes 100 patients with MASLD (51% with mild\/no fibrosis and 49% with significant fibrosis) and 50 healthy controls. Compared with healthy controls, MASLD patients had higher plasma concentrations of propionate (21.8%, 95% CI 3.33 to 43.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), formate (21.9%, 95% CI 6.99 to 38.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), valerate (35.7%, 95% CI 4.53 to 76.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), and \u03b1-methylbutyrate (16.2%, 95% CI 3.66 to 30.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) but lower plasma acetate concentrations (\u2212\u200930.0%, 95% CI \u2212\u200940.4 to \u2212\u200917.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among patients with MASLD, significant fibrosis was positively associated with propionate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), butyrate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), valerate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), and \u03b1-methylbutyrate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Six of eight SCFAs were significantly increased in F4 fibrosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the present study, SCFAs were associated with MASLD and fibrosis severity, but further research is needed to elucidate the potential mechanisms underlying our observations and to assess the possible benefit of therapies modulating gut microbiota.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-024-03129-7","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T04:02:07Z","timestamp":1705982527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Mira","family":"Thing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Parsberg","family":"Werge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv Eline","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias Badal","family":"Rashu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puria","family":"Nabilou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Ellekaer","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Douglas","family":"Galsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Bendtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Laupsa-Borge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"issue":"1","key":"3129_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep.26319","volume":"58","author":"M Mouzaki","year":"2013","unstructured":"Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58(1):120\u20137.","journal-title":"Hepatology"},{"issue":"3","key":"3129_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","volume":"7","author":"DJ Morrison","year":"2016","unstructured":"Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189\u2013200.","journal-title":"Gut Microbes"},{"key":"3129_CR3","doi-asserted-by":"crossref","unstructured":"Bach Knudsen KE, L\u00e6rke HN, Hedemann MS, Nielsen TS, Ingerslev AK, Gundelund Nielsen DS et al. Impact of Diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients. 2018;10(10).","DOI":"10.3390\/nu10101499"},{"issue":"7480","key":"3129_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature12721","volume":"504","author":"Y Furusawa","year":"2013","unstructured":"Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446\u201350.","journal-title":"Nature"},{"key":"3129_CR5","doi-asserted-by":"publisher","first-page":"1186892","DOI":"10.3389\/fimmu.2023.1186892","volume":"14","author":"X-F Liu","year":"2023","unstructured":"Liu X-F, Shao J-H, Liao Y-T, Wang L-N, Jia Y, Dong P-J, et al. Regulation of short-chain fatty acids in the immune system. Front Immunol. 2023;14:1186892.","journal-title":"Front Immunol"},{"issue":"10","key":"3129_CR6","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","volume":"6","author":"M Rau","year":"2018","unstructured":"Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United Eur Gastroenterol J. 2018;6(10):1496\u2013507.","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"3129_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1113\/JP272613","volume":"595","author":"E Boets","year":"2017","unstructured":"Boets E, Gomand SV, Deroover L, Preston T, Vermeulen K, De Preter V, et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. J Physiol. 2017;595(2):541\u201355.","journal-title":"J Physiol"},{"issue":"6","key":"3129_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.clnu.2009.05.011","volume":"28","author":"JG Bloemen","year":"2009","unstructured":"Bloemen JG, Venema K, van de Poll MC, Olde Damink SW, Buurman WA, Dejong CH. Short chain fatty acids exchange across the gut and liver in humans measured at surgery. Clin Nutr. 2009;28(6):657\u201361.","journal-title":"Clin Nutr"},{"issue":"7800","key":"3129_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-020-2101-7","volume":"579","author":"S Zhao","year":"2020","unstructured":"Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 2020;579(7800):586\u201391.","journal-title":"Nature"},{"issue":"1","key":"3129_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/oby.2009.167","volume":"18","author":"A Schwiertz","year":"2010","unstructured":"Schwiertz A, Taras D, Sch\u00e4fer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18(1):190\u20135.","journal-title":"Obesity"},{"key":"3129_CR11","doi-asserted-by":"crossref","unstructured":"de la Cuesta-Zuluaga J, Mueller NT, \u00c1lvarez-Quintero R, Vel\u00e1squez-Mej\u00eda EP, Sierra JA, Corrales-Agudelo V et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients. 2019;11(1).","DOI":"10.3390\/nu11010051"},{"issue":"1","key":"3129_CR12","doi-asserted-by":"publisher","first-page":"12515","DOI":"10.1038\/s41598-019-48775-0","volume":"9","author":"M M\u00fcller","year":"2019","unstructured":"M\u00fcller M, Hern\u00e1ndez MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci Rep. 2019;9(1):12515.","journal-title":"Sci Rep"},{"key":"3129_CR13","doi-asserted-by":"crossref","unstructured":"Xiong J, Chen XIA, Zhao Z, Liao Y, Zhou T, Xiang Q. A potential link between plasma short\u2013 chain fatty acids, TNF\u2013 \u03b1 level and disease progression in non\u2013 alcoholic fatty liver disease. A retrospective study; 2022.","DOI":"10.3892\/etm.2022.11536"},{"issue":"489","key":"3129_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aav0120","volume":"11","author":"A Tirosh","year":"2019","unstructured":"Tirosh A, Calay ES, Tuncman G, Claiborn KC, Inouye KE, Eguchi K, et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med. 2019;11(489):1\u201314.","journal-title":"Sci Transl Med"},{"key":"3129_CR15","doi-asserted-by":"crossref","unstructured":"Adler GK, Hornik ES, Murray G, Bhandari S, Yadav Y, Heydarpour M et al. Acute effects of the food preservative propionic acid on glucose metabolism in humans. BMJ open Diabetes Res care. 2021;9(1).","DOI":"10.1136\/bmjdrc-2021-002336"},{"issue":"4","key":"3129_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41366-019-0430-0","volume":"44","author":"G Aragon\u00e8s","year":"2020","unstructured":"Aragon\u00e8s G, Colom-Pellicer M, Aguilar C, Guiu-Jurado E, Mart\u00ednez S, Sabench F, et al. Circulating microbiota-derived metabolites: a liquid biopsy? Int J Obes (Lond). 2020;44(4):875\u201385.","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"3129_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","volume":"12","author":"J Behary","year":"2021","unstructured":"Behary J, Amorim N, Jiang X-T, Raposo A, Gong L, McGovern E, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021;12(1):187.","journal-title":"Nat Commun"},{"issue":"7","key":"3129_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu15071712","volume":"15","author":"HJ Tsai","year":"2023","unstructured":"Tsai HJ, Hung WC, Hung WW, Lee YJ, Chen YC, Lee CY, et al. Circulating short-chain fatty acids and non-alcoholic fatty liver Disease Severity in patients with type 2 diabetes Mellitus. Nutrients. 2023;15(7):1\u201312.","journal-title":"Nutrients"},{"issue":"20","key":"3129_CR19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration","year":"2013","unstructured":"World Medical Association Declaration. Of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"6","key":"3129_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321.","journal-title":"Hepatology"},{"issue":"22","key":"3129_CR21","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1002\/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F","volume":"19","author":"TJ Cole","year":"2000","unstructured":"Cole TJ. Sympercents: symmetric percentage differences on the 100 log(e) scale simplify the presentation of log transformed data. Stat Med. 2000;19(22):3109\u201325.","journal-title":"Stat Med"},{"issue":"1","key":"3129_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1005973","volume":"14","author":"R Wei","year":"2018","unstructured":"Wei R, Wang J, Jia E, Chen T, Ni Y, Jia W. GSimp: a Gibbs sampler based left-censored missing value imputation approach for metabolomics studies. PLoS Comput Biol. 2018;14(1):1\u201314.","journal-title":"PLoS Comput Biol"},{"key":"3129_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmet.2019.05.012","volume":"33","author":"M Pietzke","year":"2020","unstructured":"Pietzke M, Meiser J, Vazquez A. Formate metabolism in health and disease. Mol Metab. 2020;33:23\u201337.","journal-title":"Mol Metab"},{"issue":"5","key":"3129_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","volume":"15","author":"EE Canfora","year":"2019","unstructured":"Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261\u201373.","journal-title":"Nat Rev Endocrinol"},{"key":"3129_CR25","doi-asserted-by":"publisher","first-page":"711359","DOI":"10.3389\/fmicb.2021.711359","volume":"12","author":"A Nogal","year":"2021","unstructured":"Nogal A, Louca P, Zhang X, Wells PM, Steves CJ, Spector TD, et al. Circulating levels of the short-chain fatty acid acetate mediate the Effect of the gut microbiome on visceral Fat. Front Microbiol. 2021;12:711359.","journal-title":"Front Microbiol"},{"issue":"5","key":"3129_CR26","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of Advanced Fibrosis in Human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054\u20131062e5.","journal-title":"Cell Metab"},{"key":"3129_CR27","doi-asserted-by":"crossref","unstructured":"Alhabeeb H, AlFaiz A, Kutbi E, AlShahrani D, Alsuhail A, AlRajhi S et al. Gut hormones in health and obesity: the Upcoming Role of short chain fatty acids. Nutrients. 2021;13(2).","DOI":"10.3390\/nu13020481"},{"issue":"4","key":"3129_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41588-019-0350-x","volume":"51","author":"S Sanna","year":"2019","unstructured":"Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, V\u00f5sa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600\u20135.","journal-title":"Nat Genet"},{"issue":"10","key":"3129_CR29","first-page":"11595","volume":"33","author":"O Juanola","year":"2019","unstructured":"Juanola O, Ferrusqu\u00eda-Acosta J, Garc\u00eda-Villalba R, Zapater P, Magaz M, Mar\u00edn A, et al. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB J off Publ Fed Am Soc Exp Biol. 2019;33(10):11595\u2013605.","journal-title":"FASEB J off Publ Fed Am Soc Exp Biol"},{"issue":"3","key":"3129_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.clnu.2009.10.002","volume":"29","author":"JG Bloemen","year":"2010","unstructured":"Bloemen JG, Olde Damink SWM, Venema K, Buurman WA, Jalan R, Dejong CHC. Short chain fatty acids exchange: is the cirrhotic, dysfunctional liver still able to clear them? Clin Nutr. 2010;29(3):365\u20139.","journal-title":"Clin Nutr"},{"issue":"6","key":"3129_CR31","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/hep.1840140616","volume":"14","author":"MR Clausen","year":"1991","unstructured":"Clausen MR, Mortensen PB, Bendtsen F. Serum levels of short-chain fatty acids in cirrhosis and hepatic coma. Hepatology. 1991;14(6):1040\u20135.","journal-title":"Hepatology"},{"issue":"March","key":"3129_CR32","first-page":"1","volume":"9","author":"SN Mousavi","year":"2022","unstructured":"Mousavi SN, Rayyani E, Heshmati J, Tavasolian R, Rahimlou M. Effects of Ramadan and non-ramadan intermittent fasting on gut microbiome. Front Nutr. 2022;9(March):1\u20139.","journal-title":"Front Nutr"},{"issue":"1","key":"3129_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-45054-x","volume":"13","author":"ZA Rad","year":"2023","unstructured":"Rad ZA, Mousavi SN, Chiti H. A low-carb diet increases fecal short-chain fatty acids in feces of obese women following a weight-loss program: randomized feeding trial. Sci Rep. 2023;13(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"13","key":"3129_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu14132559","volume":"14","author":"V Vinelli","year":"2022","unstructured":"Vinelli V, Biscotti P, Martini D, Del Bo\u2019 C, Marino M, Mero\u00f1o T, et al. Effects of Dietary fibers on short-chain fatty acids and gut microbiota composition in healthy adults: a systematic review. Nutrients. 2022;14(13):1\u201326.","journal-title":"Nutrients"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03129-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03129-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03129-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T04:04:58Z","timestamp":1705982698000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03129-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3129"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03129-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3579314\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was approved by The Regional Committee on Health Research Ethics, the capital region, Denmark (H-17029039). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Requirements"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author Elisabeth Douglas Galsgaard is employed at Novo Nordisk and author Adrian McCann and Johnny Laupsa-Borge are employed at Bevital AS. Author Mira Thing, Mikkel Parsberg Werge, Nina Kimer, Liv Eline Hetland, Elias Badal Rashu, Puria Nabilou, Anders Ellek\u00e6r Junker and Flemming Bendtsen declare that they have no conflict of interest. Author Lise Lotte Gluud has received speaker honorarium from Norgine, Astra Zeneca, Sobi, Alexion and Novo Nordisk, consultant honorarium from Pfizer, Becton, Dickinson and Novo Nordisk and research funding from Alexion, Gilead Sciences and Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"43"}}